This post was originally published on this site Progenics Pharmaceuticals has entered a collaboration with Veteran Affairs Greater Los Angeles Healthcare System (VAGLAHS) to support the development of new machine learning tools aimed at improving detection of prostate cancer through medical imaging. The project is the first collaborative effort in the U.S. to explore pioneering…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Precigen Doses First Patient in Phase 1 Trial of PRGN-3005 for Advanced OC
This post was originally published on this site Precigen has begun dosing participants in a Phase 1 trial testing its experimental therapy PRGN-3005 UltraCAR-T in patients with advanced, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. The open-label trial (NCT03907527), which is still recruiting patients, will be carried out in collaboration with the University of…
Triple Therapies Best, But Revlimid with Dexamethasone Could Work in Some Difficult-to-Treat Myelomas, Study Shows
This post was originally published on this site Although triple therapies with Revlimid (lenalidomide) should be prioritized in patients with relapsed or refractory multiple myeloma (RRMM), combining this therapy with dexamethasone could be effective if the patients respond partially after the first treatment cycle, according to new research. The study, “Response to First Cycle Is…
Tecentriq with Chemo Shows Promise in Untreated Advanced Urothelial Cancer
This post was originally published on this site Adding Tecentriq (atezolizumab) to standard chemotherapy reduced the risk of disease worsening or death in previously untreated patients with locally advanced or metastatic urothelial cancer, according to early results of a Phase 3 trial Also, according to Genentech — the company marketing Tecentriq — the analysis showed encouraging…
Eagle Prepares Clinical Trials of New Form of Fulvestrant to Treat ER-positive Breast Cancer
This post was originally published on this site Eagle Pharmaceuticals is preparing a pilot study that may pave the way for a pivotal clinical trial evaluating its new formulation of fulvestrant as a treatment for estrogen receptor (ER)-positive breast cancer. The company believes its new formulation will block estrogen receptors more effectively than AstraZeneca‘s original formulation, approved…
Analysis Highlights Importance of Risk Assessment in Cardiac Sarcoidosis
This post was originally published on this site A new statistical analysis of Finland’s nationwide cardiac sarcoidosis (CS) registry found that sudden cardiac death plays a significant role in the outcome of CS patients, affirming the importance of risk assessment in this patient population. The study, “Sudden death in cardiac sarcoidosis: an analysis of nationwide…
Medicare Now Covers CAR T-cell Therapy for Certain Lymphomas and Leukemias
This post was originally published on this site Medicare will provide nationwide coverage for CAR T-cell therapies, an innovative anti-cancer treatment, for certain types of lymphoma and leukemia, the Centers for Medicare & Medicaid Services (CMS) has announced. Medicare will pay for this costly therapy to all cancer patients falling under the labels approved by…
Trial Testing Potential Cancer Therapy THOR-707 Starts Dosing in Australia, Cleared to Enroll in U.S.
This post was originally published on this site A Phase 1/2 trial testing the advanced tumors treatment candidate THOR-707 has begun dosing patients in Australia — and has been cleared by the U.S. Food and Drug Administration to enroll participants in the U.S. Australia is the first country recruiting patients for the global HAMMER trial…
‘Chemopause’: Too Hot to Trot
This post was originally published on this site My boss brought it up a couple of times, but the rule was clear: Polite people don’t mention it. Norma didn’t follow that rule. She’d walk down the hall fanning herself, her sweater flung over the nearest chair and her skin suddenly flushed red. “I’m having a…
Breast, Ovarian Cancer Therapy Seen to Delay to Progression in Advanced Prostate Cancers in Phase 3 Trial
This post was originally published on this site Men with metastatic castration-resistant prostate cancer (mCRPC) given Lynparza (olaparib), a breast and ovarian cancer treatment, went a clinically meaningful longer time without disease progression or death compared to those given standard treatment with Xtandi (enzalutamide) or Zytiga (abiraterone) in a Phase 3 trial. The multicenter, open-label PROfound study…
Optimal Just-in-Time Approach Accelerates Enrollment in Trials
This post was originally published on this site Using an approach called Optimal Just-in-Time (JIT) has shortened the start of patient enrollment in clinical trials of both solid tumors and blood cancers from eight months to only two weeks. Among other advantages, the methodology also enabled the recruitment of more diverse patient populations than traditional…
‘Moving Mountains for Multiple Myeloma’ Takes Trek Challenge to Iceland
This post was originally published on this site Aiming to both inspire the multiple myeloma community and raise money to accelerate treatments, members of Moving Mountains for Multiple Myeloma (MM4MM) recently traversed Iceland’s impressive landscape. The 14-member excursion included two patients plus caregivers, family members, myeloma specialists, and individuals from organizing partners. The MM4MM initiative is a…